ReviewCurrent allergy and asthma reports2016
Common and Rare Manifestations of Neuromyelitis Optica Spectrum Disorder.
Review in Current allergy and asthma reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Anti-IL-6 Therapies for Neuromyelitis Optica Spectrum Disorders: A Systematic Review of Safety and Efficacy.Current neuropharmacology · 2021Pooled it
- Hearing Loss in Neuromyelitis Optica Spectrum Disorder: Case Report and Systematic Review.Journal of clinical medicine · 2026Review
- Syncope in AQP4-IgG-positive neuromyelitis optica spectrum disorder: a case series and literature review.Frontiers in neuroscience · 2026Article
- Risk of Peripheral Artery Disease and Venous Thromboembolism in Patients with Neuromyelitis Optic Spectrum Disorder: A Nationwide Population-Based Cohort Study.International journal of medical sciences · 2026Article
- Neuromyelitis optica spectrum disorder: Exploring the diverse clinical manifestations and the need for further exploration.Brain and behavior · 2024Review
- Pearls & Oy-sters: Syndrome of Inappropriate Antidiuretic Hormone Secretion Presenting as Neuromyelitis Optica Spectrum Disorder Flare.Neurology · 2023Article
- NMOSD-Diagnostic Dilemmas Leading towards Final Diagnosis.Brain sciences · 2022Article
- Cognitive impairment in NMOSD-More questions than answers.Brain and behavior · 2020Review
- Central Sleep Apnea Syndrome Can Complicate Neuromyelitis Optica Spectrum Disorder: A Case Report.Frontiers in pediatrics · 2020Article
- Association of severe and therapy-refractory systemic lupus erythematosus and neuromyelitis optica: a management challenge.BMJ case reports · 2018Article
- Importance of Regular and Maintenance Therapy Adherence in Neuromyelitis Optica (NMO): Lessons from a Repeating Relapse Case.The American journal of case reports · 2018Article
- Complexity and wide range of neuromyelitis optica spectrum disorders: more than typical manifestations.Neuropsychiatric disease and treatment · 2017Review
- Neuroimmunological Implications of AQP4 in Astrocytes.International journal of molecular sciences · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discovery of a highly specific biomarker of neuromyelitis optica (NMO)-the anti-aquaporin-4 (AQP4) antibody-has opened new paths to understanding disease pathogenesis and afforded a way to confirm the diagnosis in clinical practice. An important consequence of the discovery is the broadening of the spectrum of syndromes seen in the context of AQP4 autoimmunity. These syndromes have been subsumed under the rubric of NMO spectrum disorder (NMOSD). The current classification recognizes not only optic neuritis and myelitis as core syndromes of NMOSD but also cerebral, diencephalic, brainstem, and area postrema syndromes. These neurologic syndromes are the focus of our review. AQP4 is also expressed in many organs outside of the central nervous system, and this may explain some of the unusual, non-neurologic features that have been occasionally reported in NMOSD. Our review catalogues non-neurologic manifestations seen in NMOSD and concludes with a discussion of frequently associated autoimmune and neoplastic comorbidities of NMOSD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.